Alacrita Appoints Peter Traber to Lead Consulting on Antifibrotic Drug Development

Thursday, September 6, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, September 6, 2018 /PRNewswire/ --

Alacrita, a leading life sciences consulting firm, today announced

that it has appointed Peter G. Traber, MD, as Partner in its Waltham, MA office. Peter is a distinguished scientist and gastroenterologist/hepatologist with over 30 years of experience.
He will support clients on a range of drug development, clinical, and strategic challenges, with a particular focus on liver and other organ fibrosis, NASH, and GI pharma consulting.

Peter brings extensive medical leadership experience and deep expertise in fibrosis, hepatology, and gastroenterology. Most recently, he led Galectin Therapeutics as CEO and CMO where he advanced a galectin-3 inhibitor, a putative antifibrotic drug, from discovery through development to a phase 3-ready program in NASH cirrhosis and built a pipeline of other indications for the drug. Prior to this, he served as Senior Vice President and CMO at GlaxoSmithKline overseeing a broad range of therapeutic areas and drug development activities.

In academic medicine, Peter served as Chief of Gastroenterology, Chairman of Medicine and CEO of the University of Pennsylvania School of Medicine and Health System. During his tenure there Peter led a basic science laboratory program that made fundamental discoveries in liver and intestinal biology. Peter also served as President and CEO of Baylor College of Medicine.

Peter obtained an MD degree from Wayne State University School of Medicine and his board certifications from the Feinberg School of Medicine at Northwestern. He holds a BS degree in chemical engineering from the University of Michigan and a certificate in business leadership for physicians from The Wharton School.

Dr. Traber possesses a rare breadth of expertise and vision that allows him to advise clients on solutions to some of the most complex scientific, clinical and strategic challenges they may face, both in their drug discovery and development programs and organizationally.

Rob Johnson, Managing Partner at Alacrita, said: "We could not be more pleased to welcome Peter onto the Alacrita team. He brings in a truly exceptional level of expertise, especially in antifibrotic drug development and NASH. There is no doubt our clients will benefit greatly from his vision and his work and leadership on the forefront of drug development." Peter Traber, Partner at Alacrita, said: "I am very excited for the new challenges Alacrita brings in biotech and pharma consulting. I truly look forward to serving the industry in this new capacity with the full scope of my knowledge gained over 30 years as a scientist, clinical researcher, and physician executive."

Dr. Traber will be routinely publishing articles and industry insight on NASH and antifibrotic drug development. For more information please visit https://www.alacrita.com/consultants/peter-g-traber/

About Alacrita  

Alacrita is a global life sciences consulting firm providing expertise-based consulting services to the pharmaceutical and biotechnology sectors. The firm's experts combine extensive industry experience (strategic, technical and commercial), advanced functional capabilities and a track record of success across the domain.

SOURCE Alacrita



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store